

Global Pneumovax 23 Market Outlook 2025-2034: Growth Drivers, Share, And Trends

The Business Research Company's Pneumovax 23 Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, February 6, 2025 /EINPresswire.com/ -- What Does the Pneumovax 23 Market Size Indicate?



The <u>Pneumovax 23 market</u> has observed a growth rate of XX HCAGR in recent years and is expected to evolve from \$XX million in 2024 to \$XX million in 2025, signifying a compound annual growth rate CAGR of XX%. The robust growth in the historic period is attributed to an increase in government vaccination programs, a rising prevalence of pneumococcal infections



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research
Company

and chronic conditions, an increment in healthcare expenditure, and a heightened focus on global immunization initiatives.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.as px?id=20333&type=smp

How Does the Pneumovax 23 Market Look in the Future? Taking a peek into the future, the Pneumovax 23 market is

predicted to grow exponentially in the next few years, reaching \$XX million in 2029 at a compound annual growth rate CAGR of XX%. This remarkable growth in the forecast period is due to a combination of factors such as growing urbanization, a rising number of aging populations, increased prevalence of co-morbidities, more investments in healthcare infrastructure, and the increasing use of digital health platforms.

What Main Driver Can Propel the Growth of the Pneumovax 23 Market?

A key catalyst that is expected to fuel the growth of the Pneumovax 23 market is the increasing incidence of pneumococcal diseases. These infections, caused by the bacterium Streptococcus pneumoniae, include various health issues from mild conditions such as sinusitis and otitis media to severe illnesses such as pneumonia and meningitis. Factors contributing to this rise

include reduced vaccination coverage during the COVID-19 pandemic, increased risk among individuals with chronic health conditions, and the resurgence of respiratory infections after the easing of social restrictions.

Pneumovax 23, by offering immunization against 23 strains of Streptococcus pneumoniae, helps in reducing the risk of infections such as pneumonia, meningitis, and bacteremia. This is corroborated by data from the Office for National Statistics, which highlighted that in December 2022, influenza and pneumonia were the primary contributors to excess deaths in England, with 574 extra deaths 26.2% above the typical rate. Therefore, the rising incidence of pneumococcal diseases worldwide is expected to drive the growth of the market.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pneumovax-23-global-market-report

Who Are the Major Players Operating in the Pneumovax 23 Market?

Major players operating in the market are Merck & Co. Inc. Merck Sharp & Dohme Corp.. With continuous advancements and investments under their belt, these players are playing a key role in the growth and expansion of the Pneumovax 23 market globally.

As for the market segmentation, the Pneumovax 23 market is classified by-

- 1 Formulation into Pneumococcal Polysaccharide Vaccine PPV and Pneumococcal Conjugate Vaccine PCV
- 2 Clinical Indication into pneumococcal Disease Prevention and
- 3 End User into Hospitals; Clinics; Ambulatory Surgical Centers; Pharmacies.

On the geographical front, North America reigned as the largest region in the Pneumovax 23 market in 2024. The global market spans across Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa providing a broad landscape for growth and development.

Browse for more similar reports-

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Transfusion Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Stem Cell/Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

About The Business Research Company:

Discover more about The Business Research Company, a leading market research company with

over 15000+ reports from 27 industries across 60+ geographies. With a rich repository of 1,500,000 datasets, exhaustive secondary research, and unique insights from industry leaders, we are geared to provide you all the information you need to stay ahead in the race.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company/ YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
20 7193 0708
info@tbrc.info

This press release can be viewed online at: https://www.einpresswire.com/article/783548879

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.